Skip to main content Accessibility help
×
×
Home
  • Print publication year: 2011
  • Online publication date: November 2011

16 - Postmortem studies of the brain cannabinoid system in schizophrenia

Summary
A study of cannabinoid application in vitro showed that THC appears to accumulate primarily in neurons and that transformation to its metabolite, THC-COOH, depends on the presence of glia. The authors suggested that the adverse effects of cannabinoids on the brain may occur through a combination of pathways involving cannabinoid receptor activation, accumulation of cannabinoids and their metabolites and upregulation of neuroinflammatory cytokines. Findings of persistent alteration of brain function or cognitive impairment in human cannabis users support the notion that long-term cannabis use may result in morphological alterations of brain structures that subserve attention, learning, memory, executive functions and emotional processes. Since brain structural changes are evident in patients with schizophrenia, cannabis may exert greater adverse effects on brain morphology when the brain is already compromised. This chapter proposes that long-term heavy cannabis use leads to structural brain changes and associated deleterious functional sequelae that resemble aspects of schizophrenia.
Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Marijuana and Madness
  • Online ISBN: 9780511706080
  • Book DOI: https://doi.org/10.1017/CBO9780511706080
Please enter your name
Please enter a valid email address
Who would you like to send this to *
×

References

Basavarajappa, B.S. and Hungund, B.L. (2002) Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overview. Prostaglandins Leukot Essent Fatty Acids, 66:287–99.
Benito, C., Tolon, R.M., Pazos, M.R., Nunez, E., Castillo, A.I. and Romero, J. (2008) Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol, 153:277–85.
Breivogel, C.S., Griffin, G., Di, M.V. and Martin, B.R. (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol, 60:155–63.
D’Souza, D.C., Abi-Saab, W.M., Madonick, S., et al. (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry, 57:594–608.
Dean, B., Bradbury, R. and Copolov, D.L. (2003) Cannabis-sensitive dopaminergic markers in postmortem central nervous system: changes in schizophrenia. Biol Psychiatry, 53:585–92.
Dean, B., Sundram, S., Bradbury, R., Scarr, E. and Copolov, D. (2001) Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience, 103:9–15.
Deng, C., Han, M. and Huang, X.F. (2007) No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia. Neurosci Bull, 23:341–7.
Di Marzo, V., Breivogel, C.S., Tao, Q., et al. (2000) Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem, 75:2434–44.
Egertova, M. and Elphick, M.R. (2000) Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J Comp Neurol, 422:159–71.
Eggan, S.M., Hashimoto, T. and Lewis, D.A. (2008) Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry, 65:772–84.
Eggan, S.M. and Lewis, D.A. (2007) Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb Cortex, 17:175–91.
Eggan, S.M., Stoyak, S.R., Verrico, C.D. and Lewis, D.A. (2010) Cannabinoid CB1 Receptor Immunoreactivity in the Prefrontal Cortex: Comparison of Schizophrenia and Major Depressive Disorder. Neuropsychopharmacology, 35:2060–71.
Elphick, M.R. and Egertova, M. (2001) The neurobiology and evolution of cannabinoid signalling. Phil Trans R Soc Lond B, 356:381–408.
Glass, M., Dragunow, M. and Faull, R.L. (1997) Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the foetal, neonatal and adult human brain. Neuroscience, 77:299–318.
Glass, M., Dragunow, M. and Faull, R.L. (2000) The pattern of neurodegeneration in Huntington’s disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington’s disease. Neuroscience, 97:505–19.
Glass, M., Faull, R.L. and Dragunow, M. (1993) Loss of cannabinoid receptors in the substantia nigra in Huntington’s disease. Neuroscience, 56:523–7.
Harrison, P.J. and Weinberger, D.R. (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry, 10:40–68.
Hashimoto, T., Arion, D., Unger, T., et al. (2008) Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry, 13:147–61.
Herkenham, M., Lynn, A.B., Little, M.D., et al. (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA, 87:1932–6.
Hoehe, M.R., Caenazzo, L., Martinez, M.M., et al. (1991) Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14-q15. New Biol, 3:880–5.
Hoffman, A.F. and Lupica, C.R. (2000) Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J Neurosci, 20:2470–9.
Kim, J. and Alger, B.E. (2004) Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nat Neurosci, 7:697–8.
Koethe, D., Llenos, I.C., Dulay, J.R., et al. (2007) Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm, 114:1055–63.
Mailleux, P., Parmentier, M. and Vanderhaeghen, J.J. (1992) Distribution of cannabinoid receptor messenger RNA in the human brain: an in situ hybridization histochemistry with oligonucleotides. Neurosci Lett, 143:200–4.
Makara, J.K., Mor, M., Fegley, D., et al. (2005) Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci, 8:1139–41.
Marco, E.M., Granstrem, O., Moreno, E., et al. (2007) Subchronic nicotine exposure in adolescence induces long-term effects on hippocampal and striatal cannabinoid-CB1 and mu-opioid receptors in rats. Eur J Pharmacol, 557:37–43.
Matsuda, L.A. (1997) Molecular aspects of cannabinoid receptors. Crit RevNeurobiol, 11:143–66.
Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C. and Bonner, T.I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346:561–4.
Mechoulam, R. and Hanus, L. (2000) A historical overview of chemical research on cannabinoids. Chem Phys Lipids, 108:1–13.
Newell, K.A., Deng, C. and Huang, X.F. (2006) Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res, 172:556–60.
Newell, K.A., Zavitsanou, K., Jew, S.K. and Huang, X.F. (2007) Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 31:225–33.
Nunez, E., Benito, C., Pazos, M.R., et al. (2004) Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse, 53:208–13.
Ong, W.Y. and Mackie, K. (1999) A light and electron microscopic study of the CB1 cannabinoid receptor in primate brain. Neuroscience, 92:1177–91.
Pertwee, R.G. (2010) Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem, 17:1360–81.
Piomelli, D. (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci, 4:873–84.
Schlicker, E. and Kathmann, M. (2001) Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci, 22:565–72.
Shire, D., Carillon, C., Kaghad, M., et al. (1995) An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem, 270:3726–31.
Sundram, S., Copolov, D. and Dean, B. (2005) Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn Schmiedebergs Arch Pharmacol, 371:428–33.
Tsou, K., Brown, S., Sanudo-Pena, M.C., Mackie, K. and Walker, J.M. (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience, 83:393–411.
Tsou, K., Mackie, K., Sanudo-Pena, M.C. and Walker, J.M. (1999) Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience, 93:969–75.
Uriguen, L., Garcia-Fuster, M.J., Callado, L.F., et al. (2009) Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology (Berl), 206:313–24.
Van Sickle, M.D., Duncan, M., Kingsley, P.J., et al. (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science, 310:329–32.
Vogt, B.A., Pandya, D.N. and Rosene, D.L. (1987) Cingulate cortex of the rhesus monkey: I. Cytoarchitecture and thalamic afferents. J Comp Neurol, 262:256–70.
Westlake, T.M., Howlett, A.C., Bonner, T.I., Matsuda, L.A. and Herkenham, M. (1994) Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer’s brains. Neuroscience, 63:637–52.
Wiley, J.L., Kendler, S.H., Burston, J.J., Howard, D.R., Selley, D.E. and Sim-Selley, L.J. (2008) Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in rats. Neuropharmacology, 55:1183–90.
Wilson, R.I. and Nicoll, R.A. (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature, 410:588–92.
Zavitsanou, K., Garrick, T. and Huang, X.F. (2004) Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 28:355–60.
Zavitsanou, K. and Huang, X.F. (2002) Decreased [(3)H]spiperone binding in the anterior cingulate cortex of schizophrenia patients: an autoradiographic study. Neuroscience, 109:709–16.
Zavitsanou, K., Ward, P.B. and Huang, X.F. (2002) Selective alterations in ionotropic glutamate receptors in the anterior cingulate cortex in schizophrenia. Neuropsychopharmacology, 27:826–33.